Annual CFO
-$10.29 M
+$17.62 M+63.12%
December 1, 2023
Summary
- As of February 25, 2025, ORMP annual cash flow from operations is -$10.29 million, with the most recent change of +$17.62 million (+63.12%) on December 1, 2023.
- During the last 3 years, ORMP annual CFO has fallen by -$2.03 million (-24.59%).
- ORMP annual CFO is now -321.16% below its all-time high of $4.66 million, reached on August 31, 2016.
Performance
ORMP Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$7.10 M
-$9.18 M-442.05%
September 1, 2024
Summary
- As of February 25, 2025, ORMP quarterly cash flow from operations is -$7.10 million, with the most recent change of -$9.18 million (-442.05%) on September 1, 2024.
- Over the past year, ORMP quarterly CFO has stayed the same.
- ORMP quarterly CFO is now -204.38% below its all-time high of $6.80 million, reached on August 31, 2016.
Performance
ORMP Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$7.92 M
-$6.41 M-423.74%
September 1, 2024
Summary
- As of February 25, 2025, ORMP TTM cash flow from operations is -$7.92 million, with the most recent change of -$6.41 million (-423.74%) on September 1, 2024.
- Over the past year, ORMP TTM CFO has stayed the same.
- ORMP TTM CFO is now -194.27% below its all-time high of $8.40 million, reached on November 30, 2016.
Performance
ORMP TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ORMP Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +63.1% | 0.0% | 0.0% |
| 3 y3 years | -24.6% | 0.0% | 0.0% |
| 5 y5 years | +20.4% | -117.3% | +32.9% |
ORMP Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +63.1% | -442.1% | +22.2% | -423.7% | +74.2% |
| 5 y | 5-year | -24.6% | +63.1% | -442.1% | +22.2% | -423.7% | +74.2% |
| alltime | all time | -321.2% | +63.1% | -204.4% | +22.2% | -194.3% | +74.2% |
Oramed Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.10 M(-442.1%) | -$7.92 M(+423.7%) |
| Jun 2024 | - | $2.08 M(-240.7%) | -$1.51 M(-75.7%) |
| Mar 2024 | - | -$1.48 M(+4.1%) | -$6.22 M(-39.6%) |
| Dec 2023 | -$10.29 M(-63.1%) | -$1.42 M(+104.3%) | -$10.29 M(-39.2%) |
| Sep 2023 | - | -$694.00 K(-73.7%) | -$16.94 M(-8.4%) |
| Jun 2023 | - | -$2.63 M(-52.5%) | -$18.49 M(-24.1%) |
| Mar 2023 | - | -$5.55 M(-31.2%) | -$24.34 M(-12.8%) |
| Dec 2022 | -$27.92 M(+151.0%) | -$8.06 M(+259.8%) | -$27.92 M(+4.3%) |
| Sep 2022 | - | -$2.24 M(-73.6%) | -$26.76 M(-12.7%) |
| Jun 2022 | - | -$8.49 M(-7.0%) | -$30.66 M(+10.3%) |
| Mar 2022 | - | -$9.13 M(+32.2%) | -$27.81 M(+26.8%) |
| Dec 2021 | -$11.12 M(-47.5%) | - | - |
| Nov 2021 | - | -$6.90 M(+12.4%) | -$21.93 M(+3.5%) |
| Aug 2021 | -$21.18 M(+156.3%) | -$6.14 M(+8.9%) | -$21.18 M(+21.1%) |
| May 2021 | - | -$5.64 M(+73.5%) | -$17.50 M(+15.0%) |
| Feb 2021 | - | -$3.25 M(-47.2%) | -$15.22 M(-2.4%) |
| Dec 2020 | -$8.26 M(-33.6%) | - | - |
| Nov 2020 | - | -$6.15 M(+150.3%) | -$15.60 M(+25.4%) |
| Aug 2020 | -$12.44 M(-3.9%) | -$2.46 M(-26.8%) | -$12.44 M(-6.1%) |
| May 2020 | - | -$3.36 M(-7.5%) | -$13.25 M(-2.2%) |
| Feb 2020 | - | -$3.63 M(+21.1%) | -$13.55 M(+14.8%) |
| Nov 2019 | - | -$3.00 M(-8.3%) | -$11.80 M(-8.8%) |
| Aug 2019 | -$12.94 M(-11.7%) | -$3.27 M(-10.6%) | -$12.94 M(-9.6%) |
| May 2019 | - | -$3.66 M(+94.1%) | -$14.32 M(-1.0%) |
| Feb 2019 | - | -$1.88 M(-54.4%) | -$14.47 M(-9.9%) |
| Nov 2018 | - | -$4.13 M(-11.1%) | -$16.06 M(+9.6%) |
| Aug 2018 | -$14.66 M(+151.4%) | -$4.65 M(+22.2%) | -$14.66 M(+21.6%) |
| May 2018 | - | -$3.81 M(+9.5%) | -$12.06 M(+13.7%) |
| Feb 2018 | - | -$3.48 M(+27.4%) | -$10.61 M(+5.5%) |
| Nov 2017 | - | -$2.73 M(+33.2%) | -$10.06 M(+72.5%) |
| Aug 2017 | -$5.83 M(-225.3%) | -$2.05 M(-13.1%) | -$5.83 M(-293.1%) |
| May 2017 | - | -$2.36 M(-19.5%) | $3.02 M(-4.2%) |
| Feb 2017 | - | -$2.92 M(-295.3%) | $3.15 M(-62.5%) |
| Nov 2016 | - | $1.50 M(-78.0%) | $8.40 M(+80.5%) |
| Aug 2016 | $4.66 M(-194.1%) | $6.80 M(-405.8%) | $4.66 M(-246.5%) |
| May 2016 | - | -$2.23 M(-195.7%) | -$3.18 M(+70.3%) |
| Feb 2016 | - | $2.32 M(-203.4%) | -$1.87 M(-67.8%) |
| Nov 2015 | - | -$2.25 M(+118.4%) | -$5.79 M(+17.1%) |
| Aug 2015 | -$4.95 M | -$1.03 M(+12.6%) | -$4.95 M(+4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| May 2015 | - | -$914.00 K(-43.0%) | -$4.72 M(-2.5%) |
| Feb 2015 | - | -$1.60 M(+14.7%) | -$4.84 M(+2.6%) |
| Nov 2014 | - | -$1.40 M(+74.4%) | -$4.72 M(+16.0%) |
| Aug 2014 | -$4.07 M(+19.8%) | -$802.00 K(-22.6%) | -$4.07 M(+14.7%) |
| May 2014 | - | -$1.04 M(-30.1%) | -$3.55 M(-0.4%) |
| Feb 2014 | - | -$1.48 M(+98.1%) | -$3.56 M(+6.2%) |
| Nov 2013 | - | -$748.00 K(+166.4%) | -$3.35 M(-1.3%) |
| Aug 2013 | -$3.40 M(+47.6%) | -$280.80 K(-73.2%) | -$3.40 M(-1.8%) |
| May 2013 | - | -$1.05 M(-17.5%) | -$3.46 M(+5.0%) |
| Feb 2013 | - | -$1.27 M(+60.5%) | -$3.29 M(+26.1%) |
| Nov 2012 | - | -$792.80 K(+132.0%) | -$2.61 M(+13.4%) |
| Aug 2012 | -$2.30 M(+34.9%) | -$341.70 K(-61.3%) | -$2.30 M(-3.4%) |
| May 2012 | - | -$883.70 K(+49.4%) | -$2.38 M(+14.2%) |
| Feb 2012 | - | -$591.50 K(+22.2%) | -$2.09 M(+23.3%) |
| Nov 2011 | - | -$484.10 K(+14.7%) | -$1.69 M(-0.8%) |
| Aug 2011 | -$1.71 M(+20.3%) | -$422.10 K(-28.3%) | -$1.71 M(+5.4%) |
| May 2011 | - | -$588.30 K(+198.6%) | -$1.62 M(+6.4%) |
| Feb 2011 | - | -$197.00 K(-60.5%) | -$1.52 M(-12.9%) |
| Nov 2010 | - | -$498.40 K(+48.8%) | -$1.75 M(+23.1%) |
| Aug 2010 | -$1.42 M(-37.5%) | -$335.00 K(-31.8%) | -$1.42 M(-10.4%) |
| May 2010 | - | -$491.30 K(+16.6%) | -$1.58 M(+20.8%) |
| Feb 2010 | - | -$421.40 K(+146.9%) | -$1.31 M(-4.1%) |
| Nov 2009 | - | -$170.70 K(-65.9%) | -$1.37 M(-39.8%) |
| Aug 2009 | -$2.27 M(+23.5%) | -$500.40 K(+129.1%) | -$2.27 M(-5.4%) |
| May 2009 | - | -$218.40 K(-54.2%) | -$2.40 M(-11.0%) |
| Feb 2009 | - | -$477.10 K(-55.5%) | -$2.70 M(+8.9%) |
| Nov 2008 | - | -$1.07 M(+70.0%) | -$2.48 M(+34.9%) |
| Aug 2008 | -$1.84 M(+200.7%) | -$631.00 K(+22.2%) | -$1.84 M(+30.8%) |
| May 2008 | - | -$516.30 K(+100.3%) | -$1.40 M(+23.9%) |
| Feb 2008 | - | -$257.70 K(-40.4%) | -$1.13 M(+20.6%) |
| Nov 2007 | - | -$432.10 K(+118.0%) | -$939.20 K(+53.7%) |
| Aug 2007 | -$611.00 K(+69.0%) | -$198.20 K(-19.1%) | -$611.00 K(-7.0%) |
| May 2007 | - | -$245.00 K(+283.4%) | -$657.10 K(+25.7%) |
| Feb 2007 | - | -$63.90 K(-38.5%) | -$522.60 K(+13.6%) |
| Nov 2006 | - | -$103.90 K(-57.5%) | -$460.20 K(+27.2%) |
| Aug 2006 | -$361.60 K(+795.0%) | -$244.30 K(+121.1%) | -$361.70 K(+208.1%) |
| May 2006 | - | -$110.50 K(+7266.7%) | -$117.40 K(+1601.4%) |
| Feb 2006 | - | -$1500.00(-72.2%) | -$6900.00(+27.8%) |
| Nov 2005 | - | -$5400.00 | -$5400.00 |
| Aug 2005 | -$40.40 K | - | - |
FAQ
- What is Oramed Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals annual CFO year-on-year change?
- What is Oramed Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals quarterly CFO year-on-year change?
- What is Oramed Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Oramed Pharmaceuticals?
- What is Oramed Pharmaceuticals TTM CFO year-on-year change?
What is Oramed Pharmaceuticals annual cash flow from operations?
The current annual CFO of ORMP is -$10.29 M
What is the all time high annual CFO for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high annual cash flow from operations is $4.66 M
What is Oramed Pharmaceuticals annual CFO year-on-year change?
Over the past year, ORMP annual cash flow from operations has changed by +$17.62 M (+63.12%)
What is Oramed Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of ORMP is -$7.10 M
What is the all time high quarterly CFO for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high quarterly cash flow from operations is $6.80 M
What is Oramed Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, ORMP quarterly cash flow from operations has changed by $0.00 (0.00%)
What is Oramed Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of ORMP is -$7.92 M
What is the all time high TTM CFO for Oramed Pharmaceuticals?
Oramed Pharmaceuticals all-time high TTM cash flow from operations is $8.40 M
What is Oramed Pharmaceuticals TTM CFO year-on-year change?
Over the past year, ORMP TTM cash flow from operations has changed by $0.00 (0.00%)